Search results
Results from the WOW.Com Content Network
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
In Apotex Inc. v. Sanofi‑Synthelabo Canada Inc., it was claimed that Sanofi-Synthelabo’s patent was invalid because it covered only a selection of a prior, broader genus patent. One of the alleged grounds of invalidity was lack of novelty. The Supreme Court of Canada employed a two-part test for anticipation. In order for there to be a ...
Apotex Inc v Sanofi-Synthelabo Canada Inc, [2008] 3 S.C.R. 265, is a leading Supreme Court of Canada decision on the novelty and non-obviousness requirements for a patent in Canada. The Court rejected a challenge by the generic drug manufacturer Apotex to declare Synthelabo Canada 's patent for Plavix , an anti-coagulant drug, invalid.
Sanofi has sold over-the-counter Zantac in the U.S. and Canada since 2017. It is pulling the drug off shelves after previous recalls by some manufacturers of generic versions of the drug.
Tablets – Orlept by Wockhardt and Epilim by Sanofi; Oral solution – Orlept Sugar Free by Wockhardt and Epilim by Sanofi; Syrup – Epilim by Sanofi-Aventis; Intravenous injection – Epilim Intravenous by Sanofi; Extended release tablets – Epilim Chrono by Sanofi is a combination of sodium valproate and valproic acid in a 2.3:1 ratio.
Apotex Inc v Sanofi-Synthelabo Canada Inc; Avalglucosidase alfa ... Sanofi Biogenius Canada; ... Text is available under the Creative Commons Attribution-ShareAlike 4 ...
Rhône-Poulenc (French pronunciation: [ʁon pulɛ̃k]) was a French chemical and pharmaceutical company founded in 1928.In 1999, it merged with Hoechst AG to form Aventis.As of 2015, the pharmaceutical operations of Rhône-Poulenc are part of Sanofi and the chemicals divisions are part of Solvay group and Bayer Crop Science.
Benzbromarone is a uricosuric agent and non-competitive inhibitor of xanthine oxidase [1] used in the treatment of gout, especially when allopurinol, a first-line treatment, fails or produces intolerable adverse effects.